An international research team led by a scientist at the University of California, Riverside, has for the first time identified individual types of the human papillomavirus, or HPV, that are specifically linked to HIV infection.
With more than 35 million people worldwide living with the virus and nearly 2 million new cases each year, the human immunodeficiency virus (HIV) remains a major global epidemic.
In a proof-of-principle study, researchers at Johns Hopkins report that a certain liver immune cell called a macrophage contains only defective or inert HIV-1 copies, and aren’t likely to restart infection on their own in HIV-1-infected p
Diagnosis of HIV-1 infection in the 4-year-old child of an HIV-negative mother led to a forensic analysis to determine the source of the infection and try to date the transmission of the virus.
In the quest to develop a vaccine that triggers the immune system to prevent HIV infection, researchers have focused on identifying and eliciting a particular type of antibody that is capable of neutralizing the virus.
A clinical trial testing infusions of combination antibodies in people living with HIV has begun at the National Institutes of Health.
Nigerian youth are at the epicenter of an expanding HIV crisis in Sub-Saharan Africa.
The National Institutes of Health has awarded $7.5 million for an international research program to prevent and treat HIV infection among adolescents and young adults in seven African countries and Brazil.
Most HIV patients need to take daily anti-retroviral therapy -- if they suspend treatment, HIV will rebound within three to four weeks.
A small number of people who are infected with HIV-1 produce very special antibodies. These antibodies do not just fight one virus strain, but neutralize almost all known virus strains.